Vega Therapeutics Inc.

Research activity is concentrated on von Willebrand Disease, with clinical interest in preventing bleeding events in adolescent and adult patients. The sponsor’s work is centered on prophylactic treatment strategies for individuals who have not previously received von Willebrand Factor-containing concentrates on a routine preventive basis.

• Bleeding event prevention
• Prophylaxis in von Willebrand Disease
• Subcutaneous therapy

The clinical program includes a multi-site research footprint across several countries, reflecting an interest in advancing treatment options for a rare bleeding disorder in both North America and international settings.